VistaGen Therapeutics, Inc Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 9 of 9 Posts
E VistaGen Is Prepared For 2021 Fueled By Recent Analyst Upgrades And Large Institutional Buyers
Article By: Moon Kil Woong Friday, January 8, 2021 11:59 AM EST
VistaGen’s deal with Pherin Pharmaceuticals to develop PH-94B has positioned the Company to grab a healthy share of, social anxiety, and major depression markets.
In this article: JNJ, SAGE, CNSP, AXSM, RLMD, VTGN
Read
VistaGen Therapeutics Announces Positive Meeting With FDA Regarding Pivotal Phase 3 Study Of PH94B For Acute Treatment Of Anxiety In Patients With Social Anxiety Disorder
Article By: TalkMarkets Newswire Thursday, July 23, 2020 9:00 AM EST
VistaGen and the FDA reached consensus on key aspects of a unique initial pivotal Phase 3 clinical trial of PH94B involving a single-event, laboratory-simulated public speaking challenge in adult patients with SAD.
In this article: VTGN Also: IMMP, ARTX, SAGE, RLMD, BHVN
Read
Week In Review: VistaGen Out-Licenses China/Asia Rights For Novel Anxiety Drug To EverInsight In $177 Million Deal
Article By: ChinaBio® Today Saturday, June 27, 2020 2:00 PM EST
VistaGen of South San Francisco out-licensed China/Southeast Asia rights for a novel anxiety treatment to EverInsight Therapeutics, a China in-licensing company, in a $177 million agreement.
In this article: VTGN Also: AGEN, HCM, GTHX, SEQUX, GILD, MRK
Read
VistaGen Therapeutics And EverInsight Therapeutics Enter Strategic Collaboration To Develop And Commercialize PH94B For Anxiety Disorders In Greater China, South Korea And Southeast Asia
Article By: TalkMarkets Newswire Thursday, June 25, 2020 8:03 AM EST
The collaboration is intended to support Phase 3 development and commercialization of PH94B in key Asian markets. The agreement includes a $5 million upfront payment and development and commercial milestones up to $172 million.
In this article: VTGN Also: ARTX, SAGE, RLMD, BHVN
Read
E VistaGen Therapeutics: Interesting Prospects
Article By: Terry Chrisomalis Tuesday, October 3, 2017 10:54 AM EST
VistaGen's drug AV-101 has breakthrough potential for treatment of depression and other indications.
In this article: VTGN Also: AGN
Read
Let's Talk Depression And How To Play The NMDA Buzz
Article By: Jason Napodano Thursday, April 6, 2017 12:21 PM EST
I think VistaGen's stock has tremendous upside potential that today's price. The company is likely to raise cash at some point over the next several months.
In this article: VTGN Also: AGN, JNJ, SAGE
Read
Some Quick Thoughts On VistaGen
Article By: Jason Napodano Wednesday, February 15, 2017 1:04 AM EST
On February 13, 2017, VistaGen Therapeutics provided a business and financial update following results of the quarter ending December 31, 2016. Here is a quick review of some of the recent happenings at the company.
In this article: VTGN Also: ALKS, ONVO
Read
VistaGen Licenses Regenerative Medicine Technology To BlueRock Therapeutics
Article By: Jason Napodano Thursday, December 15, 2016 10:41 AM EST
The agreement provides some nice potential upside in terms of future milestones and royalties from BlueRock. It also provides VistaGen a roadmap to monetize other aspects of its hPSC platform for cell therapy and regenerative medicine applications.
In this article: VTGN
Read
Could VistaGen's AV101 Be The Next Abilify?
Article By: Jason Napodano Monday, October 24, 2016 10:31 AM EST
Abilify is the single best-selling CNS drug of all time, but it's clearly not perfect. VistaGen Therapeutics looks to build upon the success of Abilify with a new approach to neurological disorders with Phase 2 candidate, AV101.
In this article: VTGN
Read
1 to 9 of 9 Posts